glp 1 2 and 3 Say What?! A Magic Medication for Weight Loss? Effects of GLP-1 and Its

JCI The magnitude of hepatic fat reduction documented in this trial substantially exceeds outcomes documented for GLP-1 mono-agonist approaches in comparable MASLD populations, providing direct investigational evidence that GCGR co-activation contributes hepatic fat clearance beyond what GLP-1 agonism alone achieves

Participants were male and female adults aged 18 years who were of non-childbearing potential and met the BMI inclusion criteria of either 30.0 kg/m, or 27.0 kg/m with hypertension or dyslipidemia

Any unused mixture should be refrigerated immediately and kept away from light and moisture [18]

Maintenance (week 17 onward, 2.4 mg): the dose carried through the 68-week trial endpoint

Neste vdeo, a nutricionista Marcella Campos Lima da Luz, do Hospital das Clnicas da Universidade Federal de Pernambuco, apresenta detalhes do estudo conduzido com o produto Trophic EP, cujos resultados foram apresentados durante o Ganepo 2025